Therapeutic protein–drug interaction assessment for daclizumab high-yield process in patients with multiple sclerosis using a cocktail approach -

Therapeutic protein–drug interaction assessment for daclizumab high-yield process in patients with multiple sclerosis using a cocktail approach
Information type: Other primary research
Source: British Journal of Clinical Pharmacology
Specialities: Neurological disorders
Summary
This study (n=29) found that daclizumab had no effect on CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A enzyme activity.
UKMi comment
Daclizumab is a humanized monoclonal antibody and interleukin 2 receptor antagonist. It currently has a positive opinion for licensing in the EU for treatment of adults with relapsing forms of multiple sclerosis.
Related links: EU positive opinion for daclizumab in relapsing forms of multiple sclerosis